{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-100065","form_type":"8-K/A","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.145128+00:00","generated_at":"2026-05-31T07:49:42.312381+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Arcadia Biosciences discloses CEO/CFO compensation: $260k/$212k salary, stock options at $2.71","bullets":["CEO Thomas Schaefer base salary $260k/yr; 2024 target bonus 50% as CEO, 40% as CFO prorated.","CFO Mark Kawakami base salary $212,063/yr; 2024 target bonus 30% as CFO, 20% as VP Finance prorated.","Each granted options to buy 20,000 shares at $2.71, vesting over 4 years (25% one-year cliff, 36 monthly).","Schaefer and Kawakami receive 6-month severance (non-CIC) or 12-month plus full equity vest (CIC).","Agreements expire third anniversary of July 5, 2024; at-will employment confirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-100065","json":"https://secwatch.observer/filing/0000950170-24-100065.json","markdown":"https://secwatch.observer/filing/0000950170-24-100065.md","text":"https://secwatch.observer/filing/0000950170-24-100065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024100065/0000950170-24-100065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024100065/rkda-20240702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:49:42.312381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}